Hartz, Richard A. published the artcileSynthesis, Structure-Activity Relationships, and In Vivo Evaluation of N3-Phenylpyrazinones as Novel Corticotropin-Releasing Factor-1 (CRF1) Receptor Antagonists, Product Details of C4H12ClNO, the publication is Journal of Medicinal Chemistry (2009), 52(14), 4173-4191, database is CAplus and MEDLINE.
Evidence suggested that corticotropin-releasing factor-1 (CRF1) receptor antagonists may offer therapeutic potential for the treatment of diseases associated with elevated levels of CRF such as anxiety and depression. A pyrazinone-based chemotype of CRF1 receptor antagonists was discovered. Structure-activity relationship studies led to the identification of numerous potent analogs including I, a highly potent and selective CRF1 receptor antagonist with an IC50 value of 0.26 nM. The pharmacokinetic properties of I were assessed in rats and Cynomolgus monkeys. Compound I was efficacious in the defensive withdrawal test (an animal model of anxiety) in rats. The synthesis, structure-activity relationships and in vivo properties of compounds, e.g., I, within the pyrazinone chemotype were described.
Journal of Medicinal Chemistry published new progress about 1162054-86-5. 1162054-86-5 belongs to ethers-buliding-blocks, auxiliary class Aliphatic Chain, name is (S)-1-Methoxypropan-2-amine hydrochloride, and the molecular formula is C4H12ClNO, Product Details of C4H12ClNO.
Referemce:
https://en.wikipedia.org/wiki/Ether,
Ether | (C2H5)2O – PubChem